SpringWorks Therapeutics, Inc.

NASDAQ:SWTX

33.09 (USD) • At close November 7, 2024
Bedrijfsnaam SpringWorks Therapeutics, Inc.
Symbool SWTX
Munteenheid USD
Prijs 33.09
Beurswaarde 2,457,693,570
Dividendpercentage 0%
52-weken bereik 18 - 53.92
Industrie Biotechnology
Sector Healthcare
CEO Mr. Saqib Islam J.D.
Website https://www.springworkstx.com

An error occurred while fetching data.

Over SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib,

Vergelijkbare Aandelen

Apollo Medical Holdings, Inc. logo

Apollo Medical Holdings, Inc.

AMEH

40.82 USD

BioCryst Pharmaceuticals, Inc. logo

BioCryst Pharmaceuticals, Inc.

BCRX

7.67 USD

Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc.

AUPH

8.34 USD

Fulgent Genetics, Inc. logo

Fulgent Genetics, Inc.

FLGT

22.02 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)